Management of high-grade gliomas in the pediatric patient: Past, present, and future

Neuro-Oncology Practice

Volumn 1, Issue 4, 2014, Pages 145-157

  Vanan, Magimairajan Issai ^a   Eisenstat, David D ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Brain tumor; Glioblastoma; High grade glioma; Pediatric

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RAS PROTEIN INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL PRACTICE; DIFFUSION TENSOR IMAGING; EVENT FREE SURVIVAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTRACRANIAL PRESSURE; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PEDIATRICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

EID: 84947075173     PISSN: 20542577     EISSN: 20542585     Source Type: Journal    
DOI: 10.1093/nop/npu022     Document Type: Article

References (105)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
2. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14:v1-v49.
3. Kaderali Z, Lamberti-Pasculli M, Rutka JT. The changing epidemiology of paediatric brain tumours: a review from the Hospital for Sick Children. Childs Nerv Syst. 2009;25(7):787-793.
4. Drappatz J, SchiffD, Kesari S, et al. Medical management of brain tumor patients. Neurol Clin. 2007;25:1035-1071.
5. Recht L, Mechtler LL, Wong ET, et al. Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy. J Clin Oncol. 2013;31:1182-1187.
6. Well EM, Gaillard DW, Parker RJ. Pediatric brain tumors and epilepsy. Semin Pediatr Neurol. 2012;19:3-8.
7. Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why and what to do about it?. Lancet Oncol. 2012;13:e375-e382.
8. Peet AC, Arvanitis TN, Leach MO, et al. Functional imaging in adult and pediatric brain tumors. Nat Rev Clin Oncol. 2012;9(12): 700-711.
9. WisoffJH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg. 1998; 89(1):52-59.
10. Kramm CM, Wagner S, Van Gool S, et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res. 2006;26:3773-3780.
11. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat. Oncol Biol Phys. 1992;24:55-57.
12. Wild-Bode C, Weller M, Rimner A, et al. Sub lethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 2001;61: 2744-2750.
13. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg. 1999;91:251-260.
14. Mizumoto M, Tsuboi K, Igaki H, et al. Phase I-II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2010;77(1):98-105.
15. Mizoe JE, Tsujii H, Hasegawa A, et al. Phase I-II clinical trial of carbon ion radiotherapy for malignant gliomas: combined x-ray radiotherapy, chemotherapy and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69(2):390-396.
16. Coombs SE, Kieser M, Rieken S, et al. Randomized phase II study evaluating carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer. 2010;10:478-486.
17. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial-a report from the Childrens Cancer Study Group. J Neurooncol. 1989;7(2):165-177.
18. MacDonald TJ, Arenson EB, Ater J, et al. Phase II study of high dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytomas: final analysis of Children's Cancer Group Study 9933. Cancer. 2005;104(12):2862-2871.
19. WolffJE, Molenkamp G, Westphal S, et al. Oral trosfosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer. 2000;89(10):2131-2137.
20. WolffJE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade gliomas. J Neurooncol. 2006;79(3):315-321.
21. WolffJE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer. 2010;116(3): 705-712.
22. WolffJE, Kortmann RD, Wolgg B, et al. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol. 2011;102(3):433-442.
23. WolffJE, Gnekow AK, Kortmann RD, et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer. 2002;94:264-271.
24. Chastagner P, Kalifa C, Doz F, et al. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) pilot study. Pediatr Blood Cancer. 2007;49:803-807.
25. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
26. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003.
27. Christians A, Hartmann C, Benner A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE. 2012;7(3):e33449.
28. Donson AM, Addo-Yobo SO, Handler MH, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48:403-407.
29. Srivastava A, Jain A, Jha P, et al. MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst. 2010;26:1613-1618.
30. Pollack IF, Hamilton RL, Sobol RW, et al. MGMT expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol. 2006;24(21):3431-3437.
31. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood. J Clin Oncol. 2002;20:4684-4691.
32. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(3):317-323.
33. Jakacki RI, Burger P, Zhou T, et al. A phase II study of concurrent radiation and TMZ followed by TMZ and lomustine (CCNU) in the treatment of children with HGG: results of COG ACNS0423. Neuro Oncol. 2010;12(6):ii1-ii134 (Page-ii12, Abstract-HGG.10).
34. 6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res. 2007;13(22):6712-6718.
35. Warren KE, Aikin AA, Libucha M, et al. Phase I study of O6-benzylguanine and TMZ administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol. 2005;23(30): 7646-7653.
36. Fangusaro J, Warren KE. Unclear standard of care for pediatric high grade glioma patients. J Neuro Oncol. 2013;113:341-342.
37. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
38. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-4729.
39. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab and irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a PBTC study. J Clin Oncol. 2010;28(18):3069-3075.
40. Narayana A, Kunnakkat S, Chacko-Matthew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12(9): 985-990.
41. Ellis M, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008;14(20):6371-6375.
42. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59(14):3374-3378.
43. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19): 5565-5570.
44. Goels S, Duda DG, Munn LL, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3): 1071-1121.
45. Chinot OL, Wick W, Mason M, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblstoma. N Engl J Med. 2014;370:709-722.
46. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699-708.
47. Fine HA. Bevacizumab in glioblastoma-still much to learn. N Engl J Med. 2014;370:764-765.
48. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res. 1999;5: 1786-1792.
49. Qaddoumi I, Kocak M, Pai Panindiker AS, et al. Phase II trial of erlotinib during and after radiotherapy in children with newly diagnosed high-grade gliomas. Front Oncol. 2014;4:67. Doi:10.3389/fonc.2014.00067.
50. Cabanas R, Saurez G, Rios M, et al. Treatment of children with high-grade gliomas with nimotuzumab-A-year institutional experience. MAbs. 2013;5(2):202-207.
51. Kim CY, Kim SK, Phi JH, et al. A prospective study of temozolomide and thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neuro Oncol. 2010;100: 193-198.
52. Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma: close relatives or distant cousins?. Nat Rev Clin Oncol. 2012;9:400-413.
53. Tanaka S, Louis DN, Curry TW, et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat Rev Clin Oncol. 2013;10(1):14-26.
54. Sturm D, Bender S, Jones DTW, et al. Paediatric and adult glioblastoma multiform (epi)genomic culprits emerge. Nat Rev Cancer. 2014;14:92-107.
55. Sturm D, Witt H, Hovestadt H, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425-437.
56. Paugh BS, Broniscer A, Qu C, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell cycle regulatory genes in diffuse intrinsic pontine gliomas. J Clin Oncol. 2011;29:3999-4006.
57. Puget S, Phillip C, Bax DA, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLos ONE. 2012;7: e30313.
58. Zhargooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric DIPG highlights PDGFRA and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010; 28:1337-1344.
59. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28:3061-3068.
60. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9:145-160.
61. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25(10): 1196-1208.
62. Massimino M, Gandola L, Luksch R, et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol. 2005; 7(1):41-48.
63. Finlay JL, Dhall G, Boyett JM, et al. Children's Cancer Group. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51(6):806-811.
64. Geyer JR, Finlay JL, Boyett JM, et al. Survival of infants with malignant astrocytomas. A Report from the Childrens Cancer Group. Cancer. 1995;75(4):1045-1050.
65. Duffner PK, Krischer JP, Burger PC, et al. Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol. 1996;28(2-3):245-256.
66. Dufour C, Grill J, Lellouch-Tubiana A, et al. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer. 2006;42(17):2939-2945.
67. Warren KE, Gururangan S, Geyer JR, et al. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol. 2012;106(3):643-649.
68. MacDonald TJ, Vezina G, Stewart CF, et al. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2013;15(10):1438-1444.
69. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226-231.
70. Fontebasso AM, Liu XY, Sturm D, et al. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol. 2013;23(2):210-216.
71. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 2013;125(5):659-669.
72. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340:857-861.
73. Yuen BTK, Knoepfler PS. Histone H3.3 mutations: A variant path to cancer. Cancer Cell. 2013;24:567-574.
74. Chan KM, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013;27(9):985-990.
75. Bjerke L, Mackay A, Nandhabalan M, et al. Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN. Cancer Discov. 2013;3(5):512-519.
76. Brockmann M, Poon E, Berry T, et al. Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-Myc in childhood Neuroblastoma. Cancer Cell. 2013;24:75-89.
77. Shimomura T, Hasako S, Nakatsure Y, et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther. 2010; 9(1):157-166.
78. Cole KA, Huggins J, Laquaglia M, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA. 2011;108(8): 3336-3341.
79. Gerges N, Fontebasso AM, Albrecht S, et al. Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Genome Med. 2013;5:66-77.
80. Kim W, Liau L. IDH mutations in human glioma. Neurosurg Clin N Am. 2012;23:471-480.
81. Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol. 2012;29:131-139.
82. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118:599-601.
83. Cheng Z, Gong Y, Ma Y, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res. 2013;19(7): 1748-1759.
84. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3:308-323.
85. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genetics. 2014;46(5):462-466.
86. Sanvitale CE, Kerr G, Chaikaud A, et al. A new class of small molecule inhibitor of BMP signaling. PLoS ONE. 2013;8(4):e62721.
87. Shimono K, Tung W, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-g agonists. Nat Med. 2011;17(4):454-462.
88. Cannon JE, Upton PD, Smith JC, et al. Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagoists. Br J Pharm. 2010;161:140-149.
89. Buczkowicz P, Hoeman C, Rakopoulus P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genetics. 2014;46(5):451-456.
90. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genetics. 2014;46(5):444-450.
91. Iyer R, Varela CR, Minturn JE, et al. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemother Pharmacol. 2012;70:477-486.
92. Iyer R, Evans AE, Qi X, et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 2010;16(5):1478-1485.
93. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340:626-630.
94. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340:622-626.
95. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4:116ra4.
96. Metellus P, Figarella-Branger D. Magnetic resonance metabolic imaging of glioma. Sci Transl Med. 2012;4:116ps1.
97. Dasgupta T, Haas-Kogan DA. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol. 2013;3:110.
98. Nicolaides TP, Li H, Solomon DA, et al. Targeted therapy for BRAF-V600E malignant astrocytoma. Clin Cancer Res. 2011; 17(24):7595-7604.
99. Belden S, Flaherty KT. MEK and RAF inhibitors for BRAF-mutated cancers. Expert Rev Mol Med. 2012;14:(e17):1-10.
100. Geoerger B, Hargrave D, Thomas F, et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13:109-118.
101. Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15(2):701-707.
102. Geyer JR, Stewart CF, Kocak M, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010; 46(18):3287-3293.
103. Lam C, Bouffet E, Bartels U. Nimotuzumab in pediatric glioma. Future Oncol. 2009;5(9):1349-1361.
104. Baruchel S, Sharp JR, Bartels U, et al. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer. 2009;45(13):2352-2359.
105. Geoerger B, Kieran MW, Grupp S, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer. 2012;48:253-262.